To outline key evidence-based guidelines and trials that inform cardiovascular care.
Approach:
Key Findings:
The 2026 ACC/AHA guideline provides updated dyslipidemia management strategies.
The 2025 ESC update incorporates recent evidence for dyslipidemia treatment.
The 2022 heart failure guideline emphasizes patient-centered care.
FOURIER trial supports the efficacy of evolocumab in reducing cardiovascular events.
PARADIGM-HF trial shows LCZ696's benefits in heart failure management.
EMPA-REG OUTCOME trial highlights empagliflozin's cardiovascular benefits in diabetes.
DAPA-HF trial confirms dapagliflozin's effectiveness in heart failure patients.
PREVENT risk equations assist in long-term cardiovascular risk assessment.
Interpretation:
These guidelines and trials provide a comprehensive framework for evidence-based cardiovascular care, emphasizing the importance of updated clinical practices and risk assessment tools.
Limitations:
Guidelines may not encompass all recent studies or emerging therapies.
Variability in patient populations may affect generalizability of trial results.
Conclusion:
The integration of these evidence-based essentials is crucial for optimizing cardiovascular care and improving patient outcomes.
In a 76-week randomized trial, patients with obesity without diabetes who received survodutide achieved greater weight loss and favorable changes in several metabolic measures compared with those who received placebo.
